68.6 F
San Diego
Monday, Jun 24, 2024


Nasdaq , IMNR

Immune Response Corp. is a biopharmaceutical company focused on the research and development of immune-based therapies for the prevention and treatment of human immunodeficiency virus and multiple sclerosis. Immune Response’s HIV products are based on its whole-killed virus technology, developed to stimulate HIV immune responses. Immune Response has three active IBT programs: Remune and IR103, which target HIV, and NeuroVax, which targets MS. Remune, the company’s most clinically advanced product in Phase II clinical trials, is designed to stimulate an HIV-infected individual’s immune system to attack HIV. IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant, is in Phase I/II clinical trials in Canada and the United Kingdom. NeuroVax has shown potential therapeutic value for MS. This product is also in Phase II clinical trials. As of Dec. 31, all of Immune Response’s products were in the development stage.


Total number of shares outstanding as of Nov. 12 50,600,000

Price of each share of common stock on Nov. 12 $.26

Aggregate market value as of Nov. 12 $13,156,000

Performance Record

For year ended Dec. 31, in thousands, except per-share data.

2004 2003 2002

Total revenues $323 $66 $47

Net income (loss) ($29,959) ($28,799) ($30,835)

Net income (loss) per share ($.65) ($1.02) ($3.07)

Total assets $15,696 $20,972 $14,565


John Bonfiglio, 50, director since 2003.

David Hochman, 30, director since 2004.

Martyn Greenacre, 63, director since 2003.

Robert Knowling Jr., 49, director since 2005.

Alan Rosenthal, 65, director since 2000.

Kevin Kimberlin, 52, director since 1986.

Kevin Reilly, 62, director since 2004.

Executive Compensation

Officer 2004 Cash Compensation

John Bonfiglio, chief executive officer $508,590

Michael Green, vice president, financial and chief financial officer $362,596

Georgia Theofan, vice president, clinical development $232,244

Bjorn Lydersen, former vice president, manufacturing $130,760

Significant Stock Ownership

Number of shares Percent

April 18

Kevin Kimberlin 32,430,201 43.9

Directors and officers as a group (10 people) 35,756,744 46.4

Other Information

Headquarters: 5931 Darwin Court, Carlsbad, CA 92008; (760) 431-7080; fax (760) 431-8636.

Web site: www.imnr.com.

Auditors: BDO Seidman, LLP.

Employees: 45.

Industry: Biotechnology.

Information was compiled from the company’s annual and proxy reports.


Featured Articles


Related Articles